Table 6. Outcome analysis.
Exposition time, ESKD and death incidence rates. Adjusted multivariate Cox regression (adjusted to age, sex, diabetes, blood pressure, proteinuria, smoking, CKD stage, cardiovascular comorbidities and RASB initial treatment) in matched population.
| Matched population | Non-Nephrocare Group | Nephrocare Group | Total matched population | Test |
| n | 3480 | 3480 | 6960 | |
| Death, n (%) | 1224 (35.2%) | 1032 (29.6%) | 2256 (32.4%) | |
| ESKD, n (%) | 121 (3.5%) | 273 (7.8%) | 394 (5.7%) | |
| KRT Modality: HD-PD, n (%) | 112 (92.6%)- 9 (7.4%) | 242 (88.6%)-31 (11.4%) | 354 (89.8%)-40 (10.2%) | p = 0.234a |
| KRT planned initiation§, n (%) | 25 (21.2%) (3 no data) | 101(38.9%) (14 no data) | 126 (33.4%) (17 no data) | p<0.001 a |
| AVF used at 1st HD | 10 (11.1%) (22 no data) | 49 (27.5%) (64 no data) | 59 (22.0%) (86 no data) | p<0.001 a |
| Death + ESKD, n (%) | 1345 (38.6%) | 1305 (37.5%) | 2650 (38.0%) | |
| Follow-up time (sum) (years-patient) | 18134 | 20934 | 39068 | |
| Follow-up time (days) (median, pc25-75) | 1621 (1010–2686) | 2027 (1241–2999) | 1821 (1121–2874) | |
| eGFR_KRT (ml/min/1.73m2) (median, pc25-75) | 8.18 (5.92–10.99) | 9.33 (7.31–12.32) | 9,03 (6,73–11,96) | p = 0.000 b |
| ESKD rate (Events/100 patient-year) | 0.67 | 1.30 | 1.01 | p < 0.05c |
| Death rate (Events/100 patient-year) | 6.75 | 4.93 | 5.77 | p < 0.05 c |
| Death+ ESKD rate (Events/100 pt-year) | 7.42 | 6.23 | 6.78 | p < 0.05 c |
| Statistical model | Event | Groups contrasted | HR / OR (IC 95%) | p |
| Cox Regression d | Death | Nephrocare vs Non-adherent (Ref) | HR 0.692 (0.637–0.753) | 0.000 |
| Cox Regression d | ESKD | Nephrocare vs Non-adherent (Ref) | HR 2.041 (1.643–2.534) | 0.000 |
| Logistic Regression e | Planned KRT startf | Nephrocare vs Non-adherent (Ref)) | OR 2.191 (1.322–3.631) | 0.002 |
| Cox Regression d | ESKD+Death | Nephrocare vs Non-adherent (Ref) | HR 0.801 (0.742–0.865) | 0.000 |
| Fine and Gray (competitive risk) | ESKD (death censored) | Nephrocare vs Non-adherent (Ref) | HR 2.358 (1.868–2.976) | 0.000 |
aChi2,
b Mann-Whitney,
c Poison tests,
dCox regression, adjusted to age, sex, diabetes, blood pressure, smoking, initial CKD stage, proteinuria, cardiovascular comorbidities and RASB therapy,
eLogistic regression adjusted to age, sex, diabetes, CV comorbidities and eGFR_KRT.
CKD = Chronic Kidney Disease, eGFR_KRT = estimated Glomerular filtration rate at kidney replacement treatment start, ESKD = End Stage Kidney Disease, HD = Hemodialysis, PD = Peritoneal dialysis, AVF = Arterio-venous fistula, RASB = Renin-angiotensin system blockade.
fas stated by the attending nephrologists at chronic KRT start official authorization form.